Research peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
== Applications == Sericin has also been used in medicine and cosmetics. Due to its elasticity and tensile strength, along with a natural affinity for keratin, sericin is primarily used in medicine for wound suturing. It also has a natural infection resistance, and is used variably due to excellent biocompatibility, and thus is used commonly as a wound coagulant as well. When used in cosmetics, sericin has been found to improve skin elasticity and several anti-aging factors, including an anti-wrinkle property. This is done by minimizing water loss from the skin. To determine this, scientists ran several experimental procedures, including a hydroxyproline assay, impedance measurements, water loss from the epidermis and scanning electron microscopy to analyze the rigidity and dryness of the skin. The presence of sericin increases hydroxyproline in the stratum corneum, which in turn, decreases skin impedance, thus increasing skin moisture. Adding in pluronic and carbopol, two other ingredients that can be included in sericin gels, performs the action of repairing natural moisture factors (NMF), along with minimizing water loss and in turn, improving skin moisture.
The discovery that oral antibiotic azithromycin can be used instead of the previous standard, injected penicillin, was tested on Lihir Island from 2013 to 2014; a single oral dose of the macrolide antibiotic reduced disease prevalence from 2.4% to 0.3% at 12 months. The WHO now recommends both treatment courses (oral azithromycin and injected penicillin), with oral azithromycin being the preferred treatment. As of 2020, there were 15 countries known to be endemic for yaws, with the recent discovery of endemic transmission in Liberia and the Philippines. In 2020, 82,564 cases of yaws were reported to the WHO, and 153 cases were confirmed. The majority of the cases are reported from Papua New Guinea and with over 80% of all cases coming from one of three countries in the 2010–2013 period: Papua New Guinea, Solomon Islands, and Ghana. A WHO meeting report in 2018 estimated the total cost of elimination to be US$175 million (excluding Indonesia). In the South-East Asian Regional Office of the WHO, regional eradication efforts are focused on the remaining endemic countries in this region (Indonesia and East Timor) after India was declared free of yaws in 2016. Although yaws is highly localized and eradication may be feasible, humans may not be the only reservoir of infection.
"Exporting pine nuts to Europe". Center for the Promotion of Imports. 24 April 2019. Archived from the original on 3 January 2023. Retrieved 3 January 2023. Charles, Dan (8 October 2014). "Love Pine Nuts? Then Protect Pine Forests". NPR. Retrieved 19 April 2015.
Sources: en.wikipedia.org
Zverev then lost in the first round of Wimbledon to Arthur Rinderknech in five sets, which marked the first time he lost in the first round of a major since 2019. Zverev reached the semifinals for the first time in Canada since winning the title in 2017 after defeating the defending champion Alexei Popyrin in the quarterfinals. He lost to the eventual finalist Karen Khachanov, despite holding a match point. He rebounded in Cincinnati by advancing to his 3rd consecutive semifinal in the American Midwest, which included wins against the recent finalists from Toronto the week before, Khachanov and Ben Shelton, both of whom were notably exhausted from their Canadian campaigns. Zverev, also struggling and exhausted in his semifinal against Carlos Alcaraz, went on to lose in straight sets. In New York, he was defeated in four sets by a resurgent Félix Auger-Aliassime. Before leaving the United States, Zverev participated in the Laver Cup with Team Europe in San Francisco but lost to Team World. In the Asian swing, Zverev was defeated by frequent rival Daniil Medvedev in the quarterfinals in Beijing, and by eventual finalist Arthur Rinderknech in the third round in Shanghai. Zverev returned to form in the European indoor swing, but found himself obstructed by Jannik Sinner for the remainder of the season, losing to him in the final in Vienna, the semifinals of Nanterre, and a round-robin match in Turin. At the Davis Cup Finals, Zverev won both of his singles matches, but Germany was defeated in the semifinal tie against Spain. He ended his season ranked world No.
During the remainder of the war, Cossack units were dismounted to fight in trenches, held in reserve to exploit a rare breakthrough, or assigned various duties in the rear. Those duties included rounding up deserters, providing escorts to war prisoners, and razing villages and farms in accordance with Russia's scorched earth policy.
Experiments done in dwarf chameleons testing these hypotheses showed that chameleon taxa with greater capacity for color change had more visually conspicuous social signals but did not come from more visually diverse habitats, suggesting that color change ability likely evolved to facilitate social signaling, while camouflage is a useful byproduct. Because camouflage is used for multiple adaptive purposes in cephalopods, color change could have evolved for one use and the other developed later, or it evolved to regulate trade offs within both.
Sources: en.wikipedia.org
== Medical uses == In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole was authorized for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.
Since ALCL was thought to be diagnosed in only 1 woman in half a million, 60 women was a much higher number than would be expected. The researchers pointed out that BIA-ALCL could be fatal. If women with implants present with delayed swelling or fluid collection, cytologic studies and a test for the marker CD30 are suggested. The American Society of Plastic Surgery (ASPS) states, "CD30 is the main diagnostic test that must be performed on the seroma fluid as routine pathology or H&E staining can frequently miss the diagnosis." Diagnosis and treatment of breast implant-associated ALCL now follows standardized guidelines established by the National Comprehensive Cancer Network. The current lifetime risk of BIA-ALCL in the U.S. is unknown, but estimates have ranged between one in 70,000 and one in 500,000 women with breast implants, according to the MD Anderson Cancer Center. Countries with breast implant registries have the best data on the risks of BIA-ALCL. For example, as of October 2020, the Therapeutic Goods Administration of Australia and New Zealand reported a "1:3,345 risk with Allergan Biocell and a 1:86,029 risk with Mentor Siltex." AIn the U.S., estimates of the risk of BIA-ALCL in textured implants ranges from 1.79 per 1,000 (1 woman with BIA-ALCL per 559 implants) to 2.82 per 1,000 (1 woman per 355 implants)[2]. As of April 2022, the FDA reported 1,130 medical device reports (MDRs) of BIA-ALCL. Of those MDRs, 59 of the women died.
==== Criticism of the Dawes Rolls ==== Author Robert J. Conley has critiqued the use of the Dawes Roll to determine membership, stating that at one point he was only a registered voter in the nation but did not actually hold a CDIB card as required by the nation, leading him to leave the tribe for the UKB, which required less "documentation" at the time, but still required blood quantum. Conley condemns the Dawes Rolls for "being inefficient, faulty, even fraudulent" and stating that if "the Cherokee Nation is really serious about exercising its sovereignty and determining its membership," then it should not use the roll that "was put together by the U.S. government and then closed by the U.S. government," meaning that the nation is "not allowed to have [a current roll] by the U.S. Congress" and therefore is still subject to the settler definitions of its members. Scholars like Osage Nation member Tink Tinker critique tribes for functioning like a state, labeling it a "European construct" and wishing tribes would turn their attention from "reforming the state to (re)building the 'small, local, autonomous communities' that flourished around the world prior to 1492." They believe that this "would allow actual Indigenous sovereignty and self-determination" and that "history tells us that nations and peoples can be organized in multiple and overlapping ways.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.